VisionCare Specialist Eye Hospital Business Plan › Section 11 › Financial Plan

This section presents the integrated five-year financial projections
— income statement, balance sheet and cash-flow statement — together
with the underlying assumptions, capital and funding structure, returns
analysis, break-even and sensitivity testing. All figures are in South
African Rand. The three statements are fully integrated and internally
consistent: profit flows to retained earnings, cash movements reconcile
to the balance-sheet cash position, and the debt schedule drives both
interest expense and the balance-sheet liability.

11.1 Key Assumptions

The projections rest on a transparent, conservative set of
assumptions, summarised below. Pricing escalates at approximately 7% per
annum (in line with medical inflation), wages at 6.5% and other costs at
6%. The model deliberately adopts a measured utilisation ramp and does
not assume best-case pricing.

Table 11.1 — Key financial assumptions

11.2 Revenue Build

Revenue is built bottom-up from eight service lines, each with a
defined full-capacity volume, average net realised price and direct-cost
ratio. Annual revenue is the product of capacity, the utilisation ramp
and price escalation. The result is a revenue base that grows from
R88.4m to R237.3m over five years.

Figure 11.1

Table 11.2 — Revenue by service line

Cost Structure Detail

The Year-1 fixed cost base comprises staff costs of R24.7m and other
operating costs of R15.3m. The tables below disaggregate these into
their components; both bases escalate annually (wages at 6.5%, other
costs at 6.0%) while being spread across rising volumes, which is the
engine of margin expansion.

Table 11.3 — Year 1 other operating cost breakdown

11.3 Projected Income Statement (Profit & Loss)

The projected income statement demonstrates rapid progression from a
modest first-year profit to substantial profitability as operating
leverage takes effect. Gross margin is stable at approximately 63.4%;
the expansion in EBITDA and net margins is driven by the fixed-cost base
being spread across rising volumes.

Table 11.4 — Projected income statement, Years 1–5

Table 11.5 — Profitability margins

Figure 11.2

Figure 11.3

11.4 Projected Balance Sheet

The balance sheet strengthens steadily as retained earnings
accumulate and debt amortises. Shareholders’ equity grows from R29.6m to
R199.4m, while the term loan reduces from its opening balance to R13.5m
by Year 5. The Company maintains a healthy net-asset position
throughout.

Table 11.6 — Projected balance sheet, Years 1–5

Figure 11.4

11.5 Projected Cash-Flow Statement

The cash-flow statement confirms the project’s strong liquidity.
Operating cash flow turns firmly positive from Year 2 and grows to
R69.5m by Year 5. After funding the Year-3 expansion (R8.5m) and
servicing scheduled debt principal repayments of R6.7m per annum, the
Company accumulates a closing cash balance of R154.3m by Year 5 — ample
headroom for distributions or reinvestment.

Table 11.7 — Projected cash-flow statement, Years 1–5

Figure 11.5

11.6 Working Capital & Revenue Cycle

Working-capital management is central to liquidity in a scheme-funded
healthcare business, where reimbursement lags service delivery. The
model assumes debtors equivalent to approximately 14% of revenue
(reflecting scheme payment cycles), inventory at roughly 5% of direct
costs, and creditor funding of about 8.5% of direct and overhead costs.
A dedicated revenue-cycle function — covering pre-authorisation,
accurate coding, prompt claim submission and active collections — is
budgeted from day one to keep debtor days within target.

Table 11.8 — Working-capital projection

The working-capital buffer embedded in the funding structure (the
excess of total funding over initial capital expenditure) ensures the
Company can absorb the first-year reimbursement lag without liquidity
stress. As the business matures, improving debtor days and scale
economies in procurement progressively release cash.

11.7 Capital Expenditure & Funding

Total initial capital expenditure is R67.2m, spanning leasehold
improvements and theatre fit-out, surgical and laser platforms,
diagnostic imaging, sterilisation, the optical laboratory, IT systems
and pre-opening working capital. The funding structure combines
R28 000 000 of equity with R47 200 000 of senior debt, providing a
buffer above bare capex for working capital during the ramp.

Figure 11.7

Table 11.9 — Initial capital expenditure breakdown

Figure 11.8

Table 11.10 — Sources and uses of funds

Indicative Debt Terms & Security

The senior debt facility is structured to give lenders strong
protection while preserving operational flexibility for the Company.
Indicative terms are summarised below and are subject to negotiation and
credit approval.

Table 11.11 — Indicative senior debt terms and security

Debt-service coverage (EBITDA to total debt service) strengthens from
the outset and comfortably exceeds a typical 1.3x minimum covenant from
Year 2 onward, as shown in the debt-service schedule. The
milestone-linked drawdown structure ensures funds are released against
verified progress — site control, construction completion and
accreditation — protecting lenders during the highest-risk
pre-operational phase.

11.8 Returns, Break-Even & Sensitivity

The project generates compelling risk-adjusted returns. On unlevered
project cash flows (including a terminal value capitalising Year-5 free
cash flow at a 3% perpetual growth rate and a 14% discount rate), the
project produces:

Break-even analysis shows that the hospital reaches operating
break-even at approximately R85.0m of annualised revenue — below the
Year-1 revenue projection of R88.4m — confirming that the facility is
profitable within its first year of operation at the planned
utilisation.

Figure 11.9

Sensitivity analysis isolates the variables to which returns are most
exposed. Year-5 net profit is most sensitive to average tariff/price and
to the pace of the utilisation ramp, and considerably less sensitive to
interest-rate movements — a reassuring profile for a debt-funded
project.

Figure 11.10

Scenario analysis tests an optimistic case (faster ramp, premium-mix
uplift) and a conservative case (slower ramp, tariff pressure). The
project remains profitable and cash-generative across all three
scenarios, underscoring the resilience of the underlying economics.

Figure 11.11

11.9 Debt Service Schedule

The senior term loan of R47 200 000 amortises over seven years on a
straight-line principal basis at an indicative rate of 11.75%.
Debt-service coverage strengthens markedly as EBITDA grows, providing
comfortable headroom for lenders.

Table 11.12 — Debt service schedule and coverage

11.10 Key Financial Ratios

The ratio analysis below confirms a financially sound and improving
profile across profitability, liquidity, leverage and efficiency. Return
on equity rises strongly as retained earnings compound and the asset
base is sweated; gearing falls steadily as debt amortises and equity
grows.

Table 11.13 — Key financial ratios, Years 1–5

The deleveraging trajectory is particularly notable: net debt to
EBITDA falls below 1.0x by Year 2 and the Company moves into a net-cash
position thereafter, while EBITDA interest cover strengthens from
comfortable to very strong levels. This profile supports both prudent
debt service and the capacity to fund the Year-3 expansion without
recourse to additional external capital.

Confidential — this business plan is provided to prospective investors and lenders for evaluation purposes only and may not be reproduced or distributed without the written consent of VisionCare Specialist Eye Hospital (Pty) Ltd.